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Previewslearn whether the same susceptibilities
observed here are recapitulated in older
mice, given that most human BCC occurs
in older adults. Finally, it may be useful to
learn whether the bulge stem cells are
resistant to malignant transformation by
other oncogenes or whether this observa-
tion is unique to the Shh pathway.
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MicroRNAs play roles in developmental switching; however, their roles in human neural progenitor cells
(hNPCs) is poorly understood. In this issue of Cell Stem Cell, Delaloy et al. (2010) report that proliferation
and migration choices in hNPCs are regulated by miR-9.During brain development, human neural
stem/progenitor cells (hNPCs) generate
different classes of neurons. In the neuro-
genic phase, radial glial cells, a subset of
NPCs derived from neuroepithelial cells,
undergo extensive proliferation in the
ventricular zone to generate cortical pro-
jection neurons. These projection neurons
migrate radially into designated layers
in the cortical plate precisely orchestrated
in temporal and spatial sequences.
Simultaneously, interneurons arise in the
medial ganglionic eminence (MGE) and
migrate tangentially toward the neo-
cortex. After the neurogenic phase, brain
development shifts to a gliogenic phase
during which astrocytes and oligodendro-
cytes with limited neuronal potential are
preferentially generated. In the adult
brain, neurogenesis is restricted within
niches, in which proliferation, migration,
and neuronal differentiation are under
tight control.
Directed differentiation of pluripotent
stem cells (PSCs) offers a defined experi-
mental system in which temporal andspatial progression of NPCs during
nervous system development can be
modeled (Elkabetz et al., 2008; Okada
et al., 2008; Zhang et al., 2001). In this
issue of Cell Stem Cell, Delaloy et al.
report that microRNA-9 (miR-9) plays
an instructive role in human embryonic
stem cells (hESCs) derived NPCs at
the checkpoint at which hNPCs choose
between proliferation and migration
(Delaloy et al., 2010). The authors showed
that miR-9 knockdown led to suppressed
proliferation concomitant with increased
migration and identified stathmin, amicro-
tubule-associated protein expressed in
migrating neuroblasts in adult mouse
brain, as the main target of miR-9 regu-
lating these processes.
miRs are noncoding small RNAs that
typically bind to complementary se-
quences in the 30 UT of target mRNAs
resulting in silencing. One miR can bind
to multiple targets (100–200) and can act
as a molecular switch for developmental
genes at the posttranscriptional level
(Landgraf et al., 2007). miR-9 is expressedin the nervous system of flies, zebrafish,
and mammals, but its expression pattern
varies across species. Thus, although
miR-9 is 100% conserved in nucleotide
sequences across the species, it appears
to have diverse roles in regulating neu-
ronal development (Leucht et al., 2008;
Li et al., 2006; Zhao et al., 2009).
To study the role of miR-9 during
neuronal development in vitro, Delaloy
et al. took advantage of a sequential
neural induction protocol. Upon
neural induction, hESCs generate neural
rosettes that consist of radially arranged
columnar epithelial cells, reminiscent of
the neural tube. After mechanical dis-
sociation and suspension culture,
rosette cells grow as neurospheres and
undergo additional morphological
changes to become radial glial cell types
with neurogenic potential. These neuro-
sphere cells, similar to NPCs, downregu-
late pluripotency genes, upregulate early
NPC genes such as nestin and SOX2,
and do not express lineage markers of
mature neurons. Terminal differentiation
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generate TUJ1-positive postmitotic
neurons.
When the authors examined expression
of different miRs, they found that miR-9
was not expressed in rosette cells but
that expression of MiR-9 was turned
on at the early neurosphere stage and
increased in proliferating hNPCs before
terminal differentiation. They hypothe-
sized that miR-9 could promote expan-
sion of early hNPCs by directly regulating
a putative candidate gene. In support of
this hypothesis, the authors found that
anti-miR-9 treatment of hNPCs resulted
in a decreased proliferative rate without
causing cell death as compared to the
scrambled RNA control. Interestingly,
miR-9 knockdown was also found to
promote chain migration from the spheres
with in vitro assays. Similarly, miR-9
knockdown also enhanced tangential
migration of hNPCs toward the neocortex
when these cells were injected into the
MGE of embryonic forebrain slices. SOX2
and PAX6 expression was maintained
during miR-9 knockdown, which sug-
gests that miR-9 does not promote
differentiation of NPCs and that instead
regulation of proliferation and migration
by miR-9 occurs independently of neu-
ronal maturation.
To identify the target gene for miR-9,
Delaloy and colleagues screened candi-
date genes on the basis of two criteria:
that the expression profile inversely corre-
lated with miR-9 expression during neural
differentiation of hESCs and that the
genes were associated with proliferation
or migration. Using this approach, the
authors found that stathmin expression
was inversely correlated with miR-9 in
hNPC culture andwas found to be a direct
target of miR-9. Stathmin is a microtu-
bule-associated protein that regulates
depolymerization of microtubules in a
phosphorylation-dependent manner. In
adult mice, stathmin is expressed in neu-
rogenic niches and the rostral migratory
stream (RMS). Stathmin siRNA was previ-
ously shown to inhibit chain migration
of neuroblasts in the RMS, suggesting
that stathmin expression is important for
neuronal migration in adult rodents (Jin
et al., 2004). The authors hypothesized
that miR-9 by regulating stathmin expres-
sion was directly involved in modulating
proliferation and migration of hNPCs. To
test this, they performed epistatis experi-ments using a combination of anti-miR-9
and stathmin siRNA. On the one hand,
siRNA stathmin alone combined with
scrambled RNA control did not influence
proliferation, presumably because of
endogenous miR-9 blocking stathmin
expression. On the other hand, siRNA
statmin in both rat and human NPC
inhibited migration. When anti-miR-9 and
siRNA stathmin were combined, the
authors found that the miR-9 phenotype
was rescued such that proliferation of
hNPCs was increased, thus providing
evidence that miR-9 controls prolifera-
tion of hNPCs directly by modulating
expression of the stathmin gene at the
posttranscriptional level. Similarly, the
combination of anti-miR-9 and siRNA
stathmin failed to enhance migration
both in vitro and in embryonic brain
explants, confirming that miR-9 also
limits migration of hNPCs by directly
modulating stathmin.
Using neural induction of hESCs to
model neural development, the authors
have begun to characterize the role of
miRs in the human nervous system.
However, the findings of the present
study are somewhat at odds with a recent
report by Zhao et al., which showed that
miR-9 negatively regulates self-renewal
of adult mouse hNPCs by targeting the
orphan nuclear receptor TLX, a key regu-
lator for self-renewal of adult mouse
NPCs (Zhao et al., 2009). In the Zhao
et al. study, the authors report that TLX
is the key target for miR-9 and that
miR-9 gain of function reduced TLX
expression and induced precocious dif-
ferentiation and migration. These differ-
ences could be attributed to differences
in species (human versus mouse), in
stages of hNPCs (early versus adult
neurogenesis), in origins of NPCs (ESCs
versus brain derived), or in the experi-
mental approaches (loss of function
versus gain- of function). Indeed, in the
study by Delaloy et al., the authors report
that TLX expression first comes on in later
stages of neural induction. Thus, lack of
TLX expression in early hNPCS may
explain why these two studies came to
different conclusions. However, the two
studies raise the interesting possibility
that miR-9 may act as a regulatory switch
at different stages of neuronal differentia-
tion by interacting with multiple targets
differentially expressed in a temporal
manner.Cell Stem CThe study byDelaloy et al. also points to
the potential of developing a combined
therapy with miR technology and stem
cell transplantation. It was previously re-
ported that stathmin is expressed during
ectopic chain migration of endogenous
neuroblasts in the ischemic striatum
and cortex in rats (Jin et al., 2004). In a
separate transplantation study of cortical
ischemic stroke, human neuroblasts
migrated preferentially toward the stroke
lesion (Kelly et al., 2004). The authors
also show here that miR-9 knockdown
promotes preferential migration of trans-
planted hNPCs toward the lesion site in
a mouse model of focal ischemic injury.
Thus, miR-9 knockdown has the potential
to facilitate delivery of hNPCs (neurogenic
or gliogeneic) to injury sites in CNS trauma
such as stroke or spinal cord injury. With
additional external cues, these instructed
cells may migrate toward injury sites and
might be able to repair damage by pro-
tecting host neurons or by forming local
circuits.
In summary, Delaloy and colleagues
report here that miR-9 regulates expan-
sion and temporal progression of early
hNPCs and limits their migration. miR-9
may play multiple roles to exert opposite
biological activities depending on its
targets such as stathmin and TLX, which
are differentially expressed in different
phases of hNPCs differentiation. Further
studies aimed at investigating how dif-
ferent microRNAs can control temporal
progression of hNPCs will be important
to elucidate molecular mechanisms of
human brain development as well as for
developing potential miR-based thera-
peutic approaches.REFERENCES
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In two recent articles in Science Translational Medicine and Nature Biotechnology, Saito et al. (2010) identify
a molecular signature of acute myeloid leukemia (AML) stem cells and demonstrate that quiescent AML stem
cells become sensitized to chemotherapy after G-CSF stimulation.Acute myeloid leukemia (AML) leukemia
stemcells (LSCs) are defined asmalignant
CD34+CD38 cells that can self-renew
and can selectively give rise to serially
transplantable AML in immunodeficient
mice. Like normal hematopoietic stem
cells (HSCs), AML LSCs exist in both
cycling and noncycling (quiescent) states.
Quiescent LSCs have been shown to
reside primarily in bone marrow niches,
where they periodically enter the cell cycle
and give rise to more differentiated leu-
kemic blasts. Whereas traditional chemo-
therapy kills rapidly dividing leukemic
blasts (Figure 1A), quiescent LSCs, shown
in many studies to be highly resistant to
chemotherapy, evade treatment and give
rise to disease relapse. The development
of therapeutic strategies to target quies-
cent, chemotherapy-resistant LSCs has
therefore been a significant thrust of
recent leukemia research.
Because LSCs subvert many of the
pathways that regulate normal HSCmain-
tenance, a critical challenge has been
to find effective LSC-directed therapy
that spares normal HSC function. Current
LSC-eradication strategies have largely
focused on targeting aberrant LSC dif-
ferentiation (Geron et al., 2008; Wernig
et al., 2008), LSC self-renewal (Abrahams-
son et al., 2009), or overexpressed
LSC cell-surface proteins. For example,
CD123 (Jin et al., 2009) was recently iden-
tified as a promising molecular target
that is highly expressed in AML LSCsbut dispensable for normal HSC function.
In their Science Translational Medicine
paper, the Ishikawa group adds to this
work by identifying potential AML LSC
targets with the use of microarray profiling
(Saito et al., 2010a). Molecular signatures
of HSC and LSC populations in a mouse
model of chronic myelogenous leukemia
were recently reported (Forsberg et al.,
2010); however, in their work, Saito and
colleagues profiled human HSC and
AML LSC samples and validated pro-
tein expression of candidate genes in
quiescent AML LSC subpopulations.
Notably, Saito and colleagues report that
CD32, CD25, WT1, and HCK were selec-
tively expressed by quiescent LSCs but
were not required for maintaining normal
hematopoiesis (Saito et al., 2010a). In their
Nature Biotechnology report, the group
employed an elegant strategy for target-
ing AML LSCs. The authors found that
G-CSF treatment stimulated quiescent
LSCs to enter the cell cycle, which caused
them to become sensitized to traditional
chemotherapy (Saito et al., 2010b)
(Figure 1B).
Saito and colleagues used two inde-
pendent microarray platforms to establish
a molecular signature uniquely expressed
by primary human AML LSCs. Genes that
were found by both arrays to be highly
expressed in LSCs but to have minimal
expression in HSCs were selected for
quantitative PCR validation on the basis
of functional categories (membraneproteins, kinases, etc.) and were then
further validated with the use of flow
cytometry and immunofluorescence. The
authors then examined expression of
their candidate genes in quiescent LSCs
in vivo. On the basis of in situ analysis of
human xenografted mouse bone marrow,
the authors identified WTI and HCK as
genes specifically expressed in Ki67
LSCs residing in the endosteal niche.
WTI was previously proposed as an LSC
target gene when a knockin reporter-
gene strategy demonstrated that it is ex-
pressed in 40% of LSCs after transfor-
mation with AML1-ETO or BCR-ABL but
not in normal HSCs (Hosen et al., 2007).
HCK, a member of the Src family of tyro-
sine kinases, is normally expressed on
mature myeloid cells and interferes with
Flt-3 signaling but has not previously
been implicated in quiescent AML LSCs.
Through FACS analysis, Saito et al. also
uncovered upregulation of CD32, CD25,
CD18, and CD93 in LSCs compared with
normal HSCs. Notably, CD32 and CD25
are cell-surface receptors that are nor-
mally expressed on B and T cells but
were here found to be overexpressed in
53% of primary AML LSCs. Sorted
CD25+ AML LSCs could also transplant
disease in immunodeficient mice. CD32
expression was less clearly associated
with transplantable LSCs. Some patient
CD32+ AML cells transplanted disease,
whereas others did not, suggesting
that expression of this marker is
